Haralabos Eleftheriadis

Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial

Sobha Sivaprasad, A Toby Prevost, Joana C. Vasconcelos et al. · The Lancet · 2017 · 372 citations · Full text

Diabetic Retinopathy, Ocular Disease, Retina +7

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

Jeffrey S. Heier, Eleonora M. Lad, Frank G. Holz et al. · The Lancet · 2023 · 372 citations

Ocular Disease, Ophthalmology, Age-related Diseases +4

Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial

Andrew Lotery, Sobha Sivaprasad, Abby O’Connell et al. · The Lancet · 2020 · 218 citations · Full text

IOLMaster biometry: refractive results of 100 consecutive cases

Haralabos Eleftheriadis · British Journal of Ophthalmology · 2003 · 196 citations · Full text

Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study)

João Figueira, Emily Fletcher, Pascale Massin et al. · Ophthalmology · 2018 · 118 citations

Diabetic Retinopathy, Ocular Disease, Ophthalmology +6